Why the study?
Does intravenous esmolol differentially affect refractoriness and conduction in the fast and slow AV nodal pathways in patients with AVNRT?
Does intravenous esmolol differentially affect refractoriness and conduction in the fast and slow AV nodal pathways in patients with AVNRT?
Esmolol demonstrates differential effects on the fast and slow AV nodal pathways, which may be clinically useful for demonstrating slow pathway conduction in AVNRT patients.
No takes yet. Share an insight, caveat, or question.
May facilitate slow pathway identification in AVNRT; leaves open clinical utility, requiring prospective confirmation.
Philippon et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: